Monica Johnson
Allergy & Immunology · Schertz, TXNPI 1275509283
Payments from drug & device makers
Across 66 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$231
- CSL Behring$205
- Kaleo, Inc.$190
- GSK$151
- Takeda Pharmaceuticals U.S.A., Inc.$123
- Optinose US, Inc.$87
- plus $489 from 15 others
What the payments were for
- Speaking & faculty fees$252%
- Food & beverage$1,45098%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 8 | $231 |
| CSL Behring | 10 | $205 |
| Kaleo, Inc. | 4 | $190 |
| GSK | 9 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| Optinose US, Inc. | 4 | $87 |
| Genentech USA, Inc. | 3 | $83 |
| AstraZeneca | 5 | $77 |
| Grifols USA, LLC | 3 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Alk-abello, Inc | 2 | $34 |
| Novartis | 1 | $28 |
| Amgen | 1 | $24 |
| Pharming Healthcare, Inc. | 1 | $23 |
| Sanofi | 1 | $18 |
| AbbVie | 1 | $16 |
| Octapharma USA, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Pfizer | 1 | $14 |
| Biocryst US Sales Co., LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUVI-Q$125
How this compares
$1,475 in reported general payments places this provider in the 20th percentile of 336 allergy & immunology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,673 |
| XhanceFluticasone Propionate | 11 | $6,580 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,455 |
| Epinephrine | 13 | $2,667 |
| Azelastine Hcl | 90 | $2,225 |
| Montelukast Sodium | 74 | $960 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $773 |
| Fluticasone Propionate | 66 | $753 |
| Mometasone Furoate | 19 | $621 |
| Ipratropium Bromide | 15 | $458 |
| Famotidine | 13 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $151 | $13,67316 claims |
| Optinose US, Inc.Xhance | $87 | $6,58011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Schertz
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
- Lyndon MansfieldEl Paso$2.4M
- Dale MoharKerrville$2.3M
- Erika GonzalezSan Antonio$2.2M
- Richard WassermanDallas$1.9M
- Joseph DiazSan Antonio$1.8M
- Niran AmarWaco$840K
- Robert JacobsSan Antonio$757K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.